Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Preveceutical Medical Inc PRVCF


Primary Symbol: C.PREV

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is a cannabinoid-based... see more

Recent & Breaking News (CSE:PREV)

PreveCeutical Applies to List on the TSX Venture Exchange as a Tier 2 Issuer

Newsfile September 25, 2017

PreveCeutical reports cannabis R&D partnership

Stockhouse Editorial September 21, 2017

PreveCeutical Announces Strategic R&D Supply Agreement

Newsfile September 21, 2017

PreveCeutical Begins Trading on the OTCQB Venture Marketplace

Newsfile September 18, 2017

PreveCeutical Launches New Corporate Website

Newsfile September 15, 2017

PreveCeutical Engages the Susan Blond Group Inc. for Publicity Services and Appoints Ms. Susan Blond as Director of Publicity

Newsfile September 13, 2017

PreveCeutical(TM) Medical and Sports 1 Marketing Announce Joint Venture to Develop a Therapy for Concussions

Newsfile August 30, 2017

PreveCeutical(TM) Medical Begins Trading on the OTC Market

Newsfile August 16, 2017

PreveCeutical updates plans to expedite innovative R&D programs

Stockhouse Editorial August 14, 2017

PreveCeutical(TM) Medical Inc. Announces Requisitions to Acquire State-of-the-Art Instrumentation Expediting Suite of Research and Developments Programs

Newsfile August 14, 2017

PreveCeutical tables results from venom re-engineering project

Stockhouse Editorial August 11, 2017

PreveCeutical™ Medical Inc. Announces Preliminary Results from Phase One of its Venom Re-Engineering Project

GlobeNewswire August 11, 2017

PreveCeutical™ Medical Inc. Announces Preliminary Results from Phase One of its Venom Re-Engineering Project

GlobeNewswire August 11, 2017

PreveCeutical™ Medical Inc. Signs Letter of Intent with UniQuest Pty Limited for Research & Development Program Engineering Peptide Therapeutics for Non-Addictive Analgesics

GlobeNewswire August 8, 2017

PreveCeutical™ Medical Inc. Begins Trading on the Frankfurt Stock Exchange

GlobeNewswire August 1, 2017

Diabetes: Silence the Messenger, Don't Shoot It -- SECFilings.com

Marketwired July 27, 2017

Top 4 Companies Reinventing Cannabinoid Delivery -- CFN Media

Marketwired July 26, 2017

PreveCeutical™ Medical Inc. Launches Phase One of Venom Re-Engineering Project

GlobeNewswire July 25, 2017

PreveCeutical in deal to research diabetes, obesity treatment

Stockhouse Editorial July 17, 2017

PreveCeutical signs Research and Option Agreement with UniQuest Pty Limited for Developing Dual-Gene Therapy Treatment for Diabetes and Obesity

GlobeNewswire July 17, 2017